FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2227851183> ?p ?o ?g. }

• W2227851183 abstract "16054 Background: Three separate studies have shown increased survival for women with epithelial ovarian carcinoma treated with intraperitoneal (IP) chemotherapy. Barriers to its use have included toxicity concerns. We compared the morbidity associated with IP cisplatin- based chemotherapy and IP immunologic therapies. Methods: A retrospective cohort analysis of patients diagnosed with epithelial ovarian carcinoma treated with IP chemotherapy at a single institution from 1996–2006 was performed. Patients were separated into those who received IP Interleukin-2 or Interleukin-12 and those who received cisplatin-based IP chemotherapy. Primary endpoint was completion of the intended treatments. Complications arising from the placement or use of the catheter were deemed catheter-related and included obstruction of flow or catheter site infection. Those felt to be caused by treatment toxicity (e.g. nausea, pain, fever) or progression of disease were deemed treatment-related. Chi square test was used for all univariate analysis. Results: Seventy-five patients were identified. Thirty-five (46.6%) received IL-2 or IL-12, while 40 (53.4%) received cisplatin-based chemotherapy. There were 16 complications that led to treatment termination (21.3%). Immunologic therapy had an increased frequency of early termination (n=13, 37.1%) compared to cisplatin-based therapy (n=3, 7.5%) (p=0.002). There were 3 (8.6%) catheter-related complications in the immunologic group and 2 (5%) in the cisplatin-based group (p=0.54). Reasons for termination of therapy in the immunologic therapy group were progression of disease (n=5), catheter site infection (n=3), grade 3/4 nausea (n=3), and grade 3/4 abdominal pain (n=2). In the cisplatin therapy group, reasons for termination included catheter site infection (n=1), catheter site leak (n=1), and progression of disease (n=1). Conclusion: Local-regional immunotherapy produces significantly more complications and local symptoms than cisplatin-based regimens. Catheter complications were not significantly different between the two groups, and accounted for a small percentage of the treatment terminations in this series. No significant financial relationships to disclose." @default.
• W2227851183 created "2016-06-24" @default.
• W2227851183 creator A5002154444 @default.
• W2227851183 creator A5019299853 @default.
• W2227851183 creator A5025757664 @default.
• W2227851183 creator A5028695126 @default.
• W2227851183 creator A5070555068 @default.
• W2227851183 creator A5078798271 @default.
• W2227851183 date "2007-06-20" @default.
• W2227851183 modified "2023-09-25" @default.
• W2227851183 title "Termination of intraperitoneal chemotherapy is driven by treatment toxicity rather than catheter dysfunction" @default.
• W2227851183 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.16054" @default.
• W2227851183 hasPublicationYear "2007" @default.
• W2227851183 type Work @default.
• W2227851183 sameAs 2227851183 @default.
• W2227851183 citedByCount "0" @default.
• W2227851183 crossrefType "journal-article" @default.
• W2227851183 hasAuthorship W2227851183A5002154444 @default.
• W2227851183 hasAuthorship W2227851183A5019299853 @default.
• W2227851183 hasAuthorship W2227851183A5025757664 @default.
• W2227851183 hasAuthorship W2227851183A5028695126 @default.
• W2227851183 hasAuthorship W2227851183A5070555068 @default.
• W2227851183 hasAuthorship W2227851183A5078798271 @default.
• W2227851183 hasConcept C121608353 @default.
• W2227851183 hasConcept C126322002 @default.
• W2227851183 hasConcept C141071460 @default.
• W2227851183 hasConcept C143998085 @default.
• W2227851183 hasConcept C203092338 @default.
• W2227851183 hasConcept C2776694085 @default.
• W2227851183 hasConcept C2778239845 @default.
• W2227851183 hasConcept C2780427987 @default.
• W2227851183 hasConcept C2781267111 @default.
• W2227851183 hasConcept C29730261 @default.
• W2227851183 hasConcept C3019054536 @default.
• W2227851183 hasConcept C535046627 @default.
• W2227851183 hasConcept C71924100 @default.
• W2227851183 hasConceptScore W2227851183C121608353 @default.
• W2227851183 hasConceptScore W2227851183C126322002 @default.
• W2227851183 hasConceptScore W2227851183C141071460 @default.
• W2227851183 hasConceptScore W2227851183C143998085 @default.
• W2227851183 hasConceptScore W2227851183C203092338 @default.
• W2227851183 hasConceptScore W2227851183C2776694085 @default.
• W2227851183 hasConceptScore W2227851183C2778239845 @default.
• W2227851183 hasConceptScore W2227851183C2780427987 @default.
• W2227851183 hasConceptScore W2227851183C2781267111 @default.
• W2227851183 hasConceptScore W2227851183C29730261 @default.
• W2227851183 hasConceptScore W2227851183C3019054536 @default.
• W2227851183 hasConceptScore W2227851183C535046627 @default.
• W2227851183 hasConceptScore W2227851183C71924100 @default.
• W2227851183 hasLocation W22278511831 @default.
• W2227851183 hasOpenAccess W2227851183 @default.
• W2227851183 hasPrimaryLocation W22278511831 @default.
• W2227851183 hasRelatedWork W2381460883 @default.
• W2227851183 hasRelatedWork W2414573978 @default.
• W2227851183 hasRelatedWork W2530877275 @default.
• W2227851183 hasRelatedWork W2746579122 @default.
• W2227851183 hasRelatedWork W3139593660 @default.
• W2227851183 hasRelatedWork W3206704704 @default.
• W2227851183 hasRelatedWork W363598932 @default.
• W2227851183 hasRelatedWork W4206600817 @default.
• W2227851183 hasRelatedWork W4243635653 @default.
• W2227851183 hasRelatedWork W4250662972 @default.
• W2227851183 isParatext "false" @default.
• W2227851183 isRetracted "false" @default.
• W2227851183 magId "2227851183" @default.
• W2227851183 workType "article" @default.